Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.
about
Immunohistochemistry and alternative FISH testing in breast cancer with HER2 equivocal amplification.Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancersData mining of digitized health records in a resource-constrained setting reveals that timely immunophenotyping is associated with improved breast cancer outcomes
P2860
Her2/neu Status Determination in Breast Cancer: A Single Institutional Experience Using a Dual-Testing Approach With Immunohistochemistry and Fluorescence In Situ Hybridization.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Her2/neu Status Determination ...... escence In Situ Hybridization.
@en
Her2/neu Status Determination ...... escence In Situ Hybridization.
@nl
type
label
Her2/neu Status Determination ...... escence In Situ Hybridization.
@en
Her2/neu Status Determination ...... escence In Situ Hybridization.
@nl
prefLabel
Her2/neu Status Determination ...... escence In Situ Hybridization.
@en
Her2/neu Status Determination ...... escence In Situ Hybridization.
@nl
P2093
P2860
P356
P1476
Her2/neu Status Determination ...... escence In Situ Hybridization.
@en
P2093
Farnaz Hasteh
James P Solomon
Marie Dell'Aquila
Oluwole Fadare
P2860
P304
P356
10.1093/AJCP/AQW224
P407
P577
2017-03-11T00:00:00Z